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Following primary ocular infection, HSV-1 establishes a latent infection in the trigeminal ganglia with the complete absence
of detectable infectious virus. Recently, we showed that vaccination of BALB/cJ with HSV-1 glycoprotein K (gK), but not
other HSV-1 glycoproteins, significantly exacerbated the severity of HSV-1-induced ocular disease and herpetic dermatitis
(H. Ghiasi et al., J. Virol. 68, 2347–2354, 1994). We now report that prior vaccination with gK blocked viral clearance from
trigeminal ganglia until at least Day 56 postinfection, resulting in a chronic infection. The significance of this novel finding
with respect to potential harmful complications associated with the immune response to gK is discussed. q 1996 Academic
Press, Inc.
A hallmark of infection with herpes simplex virus tion with gK appears to impair efficient viral clearance
from the trigeminal ganglia.(HSV) is the ability of the virus to establish a latent
infection in sensory neurons with the complete ab- Groups of mice were vaccinated either once or three
times with baculovirus-expressed gK and then ocularlysence of detectable infectious virus (1 – 7). Following
ocular infection, the site of latency is the trigeminal challenged with HSV-1 strain McKrae as previously
described (9). Twenty-eight or 56 days after challenge,ganglia (TG). In SCID mice ocular infection with viru-
lent strains of HSV-1 results in death of all mice. Infec- at which times only latent virus and no infectious virus
would be expected, mice were euthanized and the righttion with a less virulent mutant resulted in a persistent
infection with the continued presence of infectious vi- TGs were individually examined by explant cocultiva-
tion as previously described (9) using Vero cells thatrus in the TG of surviving mice (8). Thus, the complete
clearance of detectable infectious virus from the TG support HSV-1 replication. As expected, none of the
TGs from mock-vaccinated mice produced cytopathicwithin the first 2 weeks following ocular infection is
at least partially dependent on an effective immune effects (CPE) on the indicator cells on Days 1, 2, or 3
of cocultivation, indicating that these TGs did not con-response.
We recently reported that vaccination of mice with tain any infectious virus (Table 1, left panel). Also as
expected, all of the mock-vaccinated TGs producedgK severely exacerbated HSV-1-induced corneal dis-
ease following ocular challenge (9). This was unique CPE by Day 10, indicating that they contained latent
HSV-1 (Table 1, right panel). In contrast to the mock-to gK vaccination, because prior vaccination with any
of the other known HSV-1 glycoproteins either had no vaccinated results, all of the TGs from mice that had
been vaccinated with gK produced CPE within the firstaffect or provided protection against HSV-1-induced
corneal disease (10 – 12). We now show that vaccina- 3 days of cocultivation (Table 1, left panel). This rapid
appearance of CPE strongly suggests that these TGs
all contained infectious virus.1 To whom correspondence and reprint requests should be ad-
To confirm that the TGs from gK-vaccinated and ocu-dressed at Ophthalmology Research, Davis Bldg 5069, Cedars-Sinai
larly challenged mice contained infectious rather thanMedical Center, 8700 Beverly Blvd., Los Angeles, CA 90048. Fax: (310)
652-8411. only latent virus, the left TG from each of the above
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TABLE 1
Detection of Infectious Virus in Trigiminal Ganglia of BALB/c Mice Vaccinated with gKa
Day 3 after cocultivation Day 10 after cocultivation
One vaccination Three vaccinations One vaccination Three vaccinations
Antigen 28 days 28 days 56 days 28 days 28 days 56 days
gKb 8/8 7/7 7/7 8/8 7/7 7/7
Mockc 0/7 0/6 0/6 7/7 6/6 6/6
a Mice were vaccinated either one or three times with gK and then challenged occularly with 2 1 105 PFU of HSV-1 strain McKrae per eye.
Trigeminal ganglia from surviving mice were isolated on either Day 28 or Day 56 after occular challenge and cocultivated with indicator (Vero) cells
to detect HSV-1 as we described previously (17).
b CPE was visible in all cocultures of TGs from gK-vaccinated mice by 24 hr post cocultivation, indicating that these TGs contained infectious
virus.
c None of the TGs from mock-vaccinated mice showed any CPE within the first 3 days post cocultivation, indicating the absence of infectious
virus in these TGs. These TGs all produced CPE by Day 10 post cocultivation, indicating that latent virus had been present in these TGs.
mice were ground up to destroy all viable cells, cell mock-vaccinated group, no virus was detected in any
eyes after Day 7 postinfection (Table 2). In contrast,debris was removed by centrifugation, and the super-
natants were plated on indicator cells. This procedure in the gK-vaccinated mice, virus was detected in a
significant number of eyes as late as 10 days postchal-detects only infectious virus. Detection of latent virus
requires the cocultivation of intact, live neurons. No lenge. Thus, vaccination with gK appeared to increase
the duration of infectious virus in tears as well as ininfectious virus was detected in any TGs from mock-
vaccinated mice (Fig. 1A). In contrast, infectious virus trigeminal ganglia.
The simplest explanation for these findings is thatwas detected in 7 of 8 (87%) TGs from mice vaccinated
once with gK and harvested 28 days postchallenge vaccination with gK somehow prevents viral clearance
and that the extended presence of infectious virus then(Fig. 1A). Similarly, infectious virus was detected in
all 7 TGs from mice vaccinated 3 times with gK and results in exacerbation of HSV-1-induced corneal dis-
ease. In addition, since the normal immune responseharvested 28 days postchallenge (Fig. 1B), and all 7
TGs from mice vaccinated 3 times with gK and har- clears all infectious virus from the TG within 2 weeks
of ocular challenge, it is likely that prior vaccinationvested 56 days postchallenge (Fig. 1C). Thus, prior
vaccination with gK appeared to prolong the acute in- with gK somehow impedes the anti-HSV-1 immune re-
sponse. We previously found that gK vaccination doesfection in the TG until at least Day 56 postinfection,
resulting in a persistent infection. This type of persis- not induce a detectable HSV-1 neutralizing antibody
response (9); however, a measurable anti-gK ELISAtent infection, in which infectious virus is present and
can be recovered by standard virological methods, has titer is generated (unpublished observation). We have
been unable to detect any other significant gK-inducedbeen termed ‘‘chronic (productive) infection’’ (13 – 16).
In similar experiments, we have never detected in- immune response. We therefore speculate that non-
neutralizing gK antibody can partially block the normalfectious virus (virus appearing during TG explant co-
cultivation prior to Day 7) during the latent phase, in anti-HSV-1 protective immune response. This could oc-
cur through two broad avenues: (1) Nonneutralizing gKthe TG of ocularly challenged mice that had been pre-
viously vaccinated with any of the other HSV-1 glyco- antibody could bind to the virus or virus-infected cells
and by stearic hindrance interfere with either the in-proteins (gB, gC, gD, gE, gG, gH, gI, gJ, gL, and gM)
(10, 12) (H. Ghiasi et al., unpublished). Thus, as with duction or the presence of a protective immune re-
sponse; (2) gK antibody could bind directly to an ele-exacerbation of HSV-1-induced corneal disease, only
vaccination with gK and not any of the other HSV-1 ment of the immune system and either interfere with
the induction of a protective response or with the func-glycoproteins, appears to impair clearance of virus
from TGs. tion of an existing immune response. It is also possible
that with a baculovirus-gK subunit vaccine, the re-To determine if gK vaccination also impaired clear-
ance of virus from the eye, BALB/c mice were vacci- sponse to gK differs from that seen during natural in-
fection, due to differences in glycosylation or presenta-nated once with gK as above and then challenged with
McKrae. Tear films were collected from 10 eyes/group tion of gK to immune surveillance.
The combination of our present results and our pre-and cultured for the presence of infectious virus. In the
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TABLE 2




postchallenge gK Mock gD
3 10/10b 10/10 8/10
5 10/10 10/10 6/10
7 10/10 7/10 0/10
10 7/10 0/10 0/10
14 0/10 0/10 0/10
21 0/10 0/10 0/10
28 0/10 0/10 0/10
a Mice were vaccinated once and 21 days later challenged occularly
with 2 1 105 PFU/eye of HSV-1 McKrae. Tears were collected on the
days indicated using a Dacron swab and plated on RS indicator cells
to determine the presence of infectious virus as we previously de-
scribed (10).
b Number of eyes with detectable virus/total number of eyes.
vious results clearly show that under certain conditions
vaccination with expressed gK can be counterproduc-
tive. Therefore, our findings suggest that it may be
prudent to exclude gK from herpes virus subunit vac-
cines.
Finally, do anti-gK antibodies play a role in natural
infection of a naive individual? Since a significant anti-
body response to novel antigen generally takes a week
or longer to develop, it is unlikely that anti-gK antibody
would be a major factor during primary infection of a
naive individual. However, recurrent infection would
likely occur in the face of an existing or primed anti-gK
antibody response. This might then produce an affect
similar to that seen with gK vaccination. In this respect,
it will be of particular interest to determine if individu-
als with more frequent and/or more severe HSV-1 re-
currences have an increased anti-gK antibody re-
sponse relative to other HSV-1-directed immune re-
FIG. 1. Infectious virus in trigeminal ganglia of mice vaccinated sponses.
with gK. BALB/c mice (6 – 8 weeks old) were vaccinated either one
time or three times (at 3-week intervals) with baculovirus-ex- ACKNOWLEDGMENT
pressed gK as we previously described (9). Each mouse was inocu-
This work was supported by Public Health Service Grant EY09224lated both ip (gK / buffer) and subcutaneously (gK / Freund’s
from the National Eye Institute.complete adjuvant for inoculation 1; gK / Freund’s incomplete ad-
juvant for inoculations 2 and 3). Each gK inoculum contained total
extract from 1 1 106 Sf9 cells infected with a baculovirus vector
expressing gK. Each inoculum contained approximately 5 – 7 mg of
gK. Mock-vaccinated mice were similarly inoculated with wild-type gation at 3000 rpm for 10 min in a Beckman TA10 rotor, and the
baculovirus-infected Sf9 cells. Three weeks after the final vaccina- supernatant used to infect Vero cell monolayers. The presence of
tion, all mice were challenged bioccularly, without corneal scarifi- infectious virus was monitored by the appearance of CPE. Latent
cation, using 2 1 105 PFU of HSV-1 strain McKrae. Surviving mice virus is not detected by this technique because reactivation from
were euthanized on Day 28 or 56 postchallenge and individual latency requires viable intact neurons. Only TGs containing infec-
trigeminal ganglia were harvested. The right TG from each mouse tious virus produce CPE in this assay (4). The percentage of TGs
was used in the experiment shown in Table 1. The left TG from containing infectious virus is shown in each bar chart, with the
each mouse was individually homogenized using a Brinkman ho- number of positive/total TGs shown at the top of each bar. (A) One
mogenizer at maximum speed. Two 1-min homogenization cycles vaccination 28 days postchallenge; (B) three vaccinations 28 days
were done on ice for each TG. The debris was removed by centrifu- postchallenge; (C) three vaccinations 56 days postchallenge.
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